Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 10/20 | 0.54 |
| ▸ | MERTK | Q12866 | 5/20 | 0.48 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.46 |
| ▸ | MET | P08581 | 4/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132352 | 0.86 | AXL (0.55) | AXLMERTKKDRPDGFRAMET | |
| SCHEMBL30066135 | 0.86 | AXL (0.55) | AXLMERTKKDRPDGFRAMET | |
| SCHEMBL29811874 | 0.85 | PDGFRB (0.54) | AXLKDRPDGFRAKITFGFR2 | |
| SCHEMBL23147176 | 0.85 | PDGFRB (0.54) | AXLKDRPDGFRAKITFGFR2 | |
| SCHEMBL21198895 | 0.84 | PDGFRA (0.51) | AXLMERTKKDRPDGFRAMET | |
| SCHEMBL21198905 | 0.83 | MET (0.57) | AXLMERTKKDRPDGFRAMET | |
| SCHEMBL1890374 | 0.81 | AXL (0.63) | AXLMERTKKDRPDGFRAMET | |
| SCHEMBL1132666 | 0.81 | AXL (0.61) | AXLMERTKKDRPDGFRAMET | |
| SCHEMBL25166708 | 0.80 | AXL (0.53) | AXLMERTKKDRPDGFRAMET | |
| SCHEMBL21198946 | 0.79 | AXL (0.81) | AXLMERTKKDRMETAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089541-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2022-03-24 | — | — | US | disclosed |
| EP-3914356-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-113710322-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2020154610-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020154610-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089541-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | PRKDC, MAP3K20, BRAF | AXL 1643/4885MERTK 614/4885KDR 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.